FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency also requests that the National Institutes of Health Foundation study Elan’s Zonegran and Genzyme’s Renagel in children. The drugs’ sponsors had declined written requests for pediatric trials.
You may also be interested in...
Eisai Acquires Elan's Zonegran; Will Detail With Aricept
Elan will receive a $130 mil. upfront payment and up to $110 mil. in milestone payments. Eisai does not plan to seek a co-promotion partner for the epilepsy agent.
Impax/Teva Launch Wellbutrin SR Generic As Andrx Relinquishes Exclusivity
The 150 mg Impax/Teva product is following Eon's and Watson's 100 mg generics to the market. Andrx will receive a share of the profits.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.